Mission Creek Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

Mission Creek Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-7,009	Closed	-$903K	–	234
2021 Q1	$903K	Buy	+7,009	New	+$1.07M	0.13%	111

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Mission Creek Capital Partners's ASND Position: Q2 2021 in Review

Mission Creek Capital Partners sold out of Ascendis Pharma A/S (ASND) in Q2 2021, closing a stake of 7,009 shares — an estimated $903K sold.

Mission Creek Capital Partners first reported a position in ASND in Q1 2021 and held it in 1 quarter. The position peaked at $903K in Q1 2021. 171 funds tracked by Wall St. Rank hold ASND as of Q2 2021.

Mission Creek Capital Partners reported no remaining Ascendis Pharma A/S position as of Q2 2021 after selling out during the quarter.
Mission Creek Capital Partners sold 7,009 Ascendis Pharma A/S shares in Q2 2021, an estimated $903K.
Mission Creek Capital Partners first reported a position in Ascendis Pharma A/S in Q1 2021 and held it in 1 quarter.
Mission Creek Capital Partners's Ascendis Pharma A/S position peaked at $903K in Q1 2021.
171 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2021.

Based on Mission Creek Capital Partners's 13F filing for Q2 2021, filed 13 Aug 2021.